BIOAGE LABS INC (BIOA) Stock Price, Quote, News and Overview
NASDAQ:BIOA - Nasdaq - US09077V1008 - Common Stock - Currency: USD
BIOA Quote, Performance and Key Statistics
4.34
-0.05 (-1.14%)
The current stock price of BIOA is 4.34 USD. In the past month the price increased by 11.28%.
BIOA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.43 | 722.87B | ||
| JNJ | JOHNSON & JOHNSON | 14.9 | 360.41B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.38 | 327.79B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 228.66B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.9 | 216.88B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.52B | ||
| PFE | PFIZER INC | 7.47 | 136.28B | ||
| SNY | SANOFI-ADR | 10.68 | 116.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.36B | ||
| GSK | GSK PLC-SPON ADR | 8.61 | 77.15B | ||
| ZTS | ZOETIS INC | 26.11 | 69.97B | ||
| HLN | HALEON PLC-ADR | 21.24 | 46.84B |
Related stock screener links
About BIOA
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Richmond California, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Company Info
BIOAGE LABS INC
1445A South 50Th Street
Richmond California CALIFORNIA H3B 4W8 US
CEO: Fabrice Orecchioni
Employees: 62
Phone: 15108061445
BIOAGE LABS INC / BIOA FAQ
What is the stock price of BIOAGE LABS INC today?
The current stock price of BIOA is 4.34 USD. The price decreased by -1.14% in the last trading session.
What is the ticker symbol for BIOAGE LABS INC stock?
The exchange symbol of BIOAGE LABS INC is BIOA and it is listed on the Nasdaq exchange.
On which exchange is BIOA stock listed?
BIOA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOAGE LABS INC stock?
9 analysts have analysed BIOA and the average price target is 4.76 USD. This implies a price increase of 9.68% is expected in the next year compared to the current price of 4.34. Check the BIOAGE LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOAGE LABS INC worth?
BIOAGE LABS INC (BIOA) has a market capitalization of 155.59M USD. This makes BIOA a Micro Cap stock.
How many employees does BIOAGE LABS INC have?
BIOAGE LABS INC (BIOA) currently has 62 employees.
What are the support and resistance levels for BIOAGE LABS INC (BIOA) stock?
BIOAGE LABS INC (BIOA) has a support level at 3.93 and a resistance level at 4.39. Check the full technical report for a detailed analysis of BIOA support and resistance levels.
Should I buy BIOAGE LABS INC (BIOA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIOA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIOA, evaluating the profitability, health, valuation and growth aspects
- BIOAGE LABS INC (BIOA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOAGE LABS INC (BIOA) Sales and EPS estimates to see what analysts future expectations are.
- BIOAGE LABS INC (BIOA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOAGE LABS INC (BIOA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOAGE LABS INC (BIOA) Stock Chart to make your own analysis
- BIOAGE LABS INC (BIOA) Latest news and press-releases to stay up to date.
Does BIOAGE LABS INC (BIOA) stock pay dividends?
BIOA does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIOAGE LABS INC (BIOA)?
BIOAGE LABS INC (BIOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.34).
What is the Short Interest ratio of BIOAGE LABS INC (BIOA) stock?
The outstanding short interest for BIOAGE LABS INC (BIOA) is 4.71% of its float. Check the ownership tab for more information on the BIOA short interest.
BIOA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BIOA.
BIOA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIOA. While BIOA seems to be doing ok healthwise, there are quite some concerns on its profitability.
BIOA Financial Highlights
Over the last trailing twelve months BIOA reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS decreased by -6.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.44% | ||
| ROE | -26.83% | ||
| Debt/Equity | 0 |
BIOA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 47% to BIOA. The Buy consensus is the average rating of analysts ratings from 9 analysts.